2/22
09:04 am
calt
Calliditas Therapeutics AB (publ) (NASDAQ: CALT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
Low
Report
Calliditas Therapeutics AB (publ) (NASDAQ: CALT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.